Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 04

481P - Second generation oral selective estrogen receptor degraders (SERDs) in breast cancer: A systematic review and meta-analysis of clinical trials

Date

21 Oct 2023

Session

Poster session 04

Topics

Tumour Site

Breast Cancer

Presenters

Maysa Silveira Vilbert

Citation

Annals of Oncology (2023) 34 (suppl_2): S334-S390. 10.1016/S0923-7534(23)01260-7

Authors

M. Silveira Vilbert1, D. Pinheiro Xavier2, M. Goldner Cesca3, L.V. Ravani4, J. Chamadoira5, C. Stecca6, R. Costa7, L. Cavalcante8

Author affiliations

  • 1 Department Of Clinical Oncology, UHN - University Health Network - Princess Margaret Cancer Center, M5G 2M9 - Toronto/CA
  • 2 Department Of Medicine, Universidade Federal do Para-Health Science Institute, 66050-160 - Belém/BR
  • 3 Department Of Clinical Oncology, A.C. Camargo Cancer Center - Fundacao Antonio Prudente, 01509-010 - Sao Paulo/BR
  • 4 Department Of Medicine, University of Sao Paulo - Faculty of Medicine, 01246-903 - Sao Paulo/BR
  • 5 Department Of Medical Imaging, St. Michael's Hospital - University of Toronto, M5B 1W8 - Toronto/CA
  • 6 Medical Oncoogy Department, Center of Oncology of Parana, 2167 - Curitiba/BR
  • 7 Breast Oncology, H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, 33612 - Tampa/US
  • 8 Medical Oncology Department, Novant Health Cancer Institute, 28204 - Charlotte/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 481P

Background

SERDs are effective treatment options for breast cancer (BC) patients (pts) after progression on first-line therapy, especially for those harboring estrogen-receptor 1 (ESR1) mutations (mut). Several studies have explored the potential of SERDs to overcome endocrine resistance, yielding promising results.

Methods

We conducted a systematic review and meta-analysis to assess oral SERDs in hormone receptor-positive, HER-2-negative BC pts. Efficacy was evaluated by tumor response according to ESR1mut, and the number of pts with variant allele frequency (VAF) decreased with SERD therapy. We searched Pubmed, Scopus, and Cochrane Library databases and congress websites for randomized and non-randomized clinical trials. We used a random effects model for data pooling; heterogeneity was assessed with I2 statistics.

Results

We included 19 studies with 1,798pts. Of 855 pts tested, 387 (45%) had ESR1mut. ESR1mut frequency and respective overall response rate (ORR) are described in the table. We found 80% of pts(95%CI 0.72-0.88 I256%) had a decrease in VAF with SERD therapy. The estimated risk of all-causality adverse events (AE) was 86% (95% CI 0.80-0.92), and grades 3 or 4 AE were 19% (95% CI 0.11-0.28). SERD plus Palbociclib resulted in higher rates of AEs (p<0.01). Elacestrant had numerically higher G3-4 AEs compared to the other SERD (p=0.05). The most common AEs were nausea (35%), diarrhea (30%), and fatigue (23%). Arthralgia was reported in 15%, and only 1% of pts had to discontinue treatment due to AE.

Table: 481P

Characterization of ESR1mut and response to SERD (amcenestrant, elacestrant, and camizestrant)

ESR1mut Prevalence of ESR1mut(%) Patients assessed for response(n) ORR(%)
D538G 34 25 44
Y537S 28 23 61
E380Q 8 8 25
Y537N 7 11 45
L536H 6 4 75
Others 16 13 15

Conclusions

Our study supports the favorable safety profile of the new generation oral SERD and presents its efficacy according to ESR1mut. Further studies shall assess the potential biomarker role of individual ESR1mut.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

M. Goldner Cesca: Financial Interests, Personal, Invited Speaker: Novartis, Daiichi Sankyo, Zodic. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.